Solvias joins forces with Enzymicals in chemocatalysis and biocatalysis

New partnership will open access to biocatalysis offerings like production of biocatalysts, customer-specific solutions to questions of chemo-biocatalytic synthesis, process development and piloting.

Solvias, one of the largest independent analytical testing, contract research, development and manufacturing companies, today announced a non-exclusive partnership with Enzymicals (Greifswald, Germany), opening access to alternative synthetic technology platforms for chemocatalysis and biocatalysis.

The ligands and specialty unit at Solvias has a proven track record in the efficient and successful development of catalytic processes, while Enzymicals, a German enterprise focusing on industrial biocatalysis, has the perfect combination of complementary services with the aim of providing solutions to challenging chemical transformations.

Customers of both partners will benefit from proprietary catalyst portfolios and expertise for catalytic transformations with a suite of related custom synthesis and technology platforms. In addition, analytical testing solutions can be provided.

In the past decade both chemocatalysis and biocatalysis have become strategic assets widely applicable to asymmetric reactions. Smart use of these processes can result in novel synthetic approaches in the area of process development with the common objective of achieving more sustainable manufacturing.

CEO of Enzymicals AG, Dr. Ulf Menyes, said: "During our successful activities in industrial biocatalysis for diverse markets, we are constantly faced with the outstanding efficiency of chemocatalysis. The incorporation of the transformational power of Solvias ligands in our propositions now enables our customers to investigate a much wider range of solutions from the beginning. In particular, the combination of both technologies within chemo-enzymatic cascades represents an innovative and currently very promising path for cost-efficient production strategies. I am really pleased that with Solvias we have a strong collaboration partner with complementary technology and expertise."

Solvias' Head of Ligands & Specialty Products, Dr. Jürgen Rotzler, said: "Overall, both chemocatalysis and biocatalysis are well-established technologies for large-scale production. The huge variety of commercially available ligands and the opportunity to tailor enzymes to specific needs by evolution provides chemists with complementary technologies to tackle everyday challenges in organic chemistry. We are very happy to now be able to add a further component to our scientists' toolbox by collaborating with Enzymicals and therefore further supporting our customers in bringing better and safer products to the market faster."